Each particle has its own charge and its own mass.

The COP is the supreme decision-making body of the Convention. All States that are Parties to the Convention are represented at the COP, at which they review the implementation of the Convention and ...

SPLASH highlighted 177Lu-PNT2002 as a promising radioligand therapy option for chemotherapy-naïve mCRPC. EORTC-GUCG 1333/PEACE-3: Radium-223 and Enzalutamide in Asymptomatic or Mildly Symptomatic ...

At ESMO 2024, Lantheus will present additional clinical data from the Phase 3 SPLASH trial on 177Lu-PNT2002, a PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer ...

The University of Oklahoma's $2.1 billion enterprise represents one of Oklahoma's greatest assets. Our impact is changing the lives of all Oklahomans, through scholarship, research and more. 30,000+ ...

If the $12.50-per-share all-cash deal is completed, it will give Lilly a stake in a PSMA-targeted radioligand therapy – PNT2002 – which is in the phase 3 SPLASH trial in patients with ...

Lantheus' pipeline includes promising assets such as PNT2002 and Alzheimer's diagnostics MK-6240 and NAV-4694, which could unlock significant market opportunities. The company expects 200-300 ...

Similarly, Point has a treatment that was going through phase 3 trials at the time of the arrangement, as the company investigated PNT2002 for the treatment of metastatic-castration resistant ...

On the eve of Republic Day, the central government on Saturday announced the list of recipients for the Padma Shri Awards 2025. The Padma awards, among the country's highest civilian honours, are ...

Lantheus' pipeline includes promising assets such as PNT2002 and Alzheimer's diagnostics MK-6240 and NAV-4694, which could unlock significant market opportunities. The company expects 200-300 basis ...